Finally, retinoids have been found to delay the onset of mammary tumors in HER2 transgenic mice [44,45], and a selective ER modulator/rexinoid combination was synergistic in the prevention or treatment of such tumors, despite the ER-negative status of such tumors [46]. This evidence concerns the gene ESR1 and breast cancer.